New Delhi: Drug firm Alkem Labs Ltd on Friday said its Daman manufacturing plant has obtained the Establishment Inspection Report (EIR) from US health regulator United States Food and Drug Administration (FDA).

“The USFDA has issued an Establishment Inspection Report for its Daman manufacturing facility which was inspected by the USFDA in September 2016,” Alkem Labs said in a Bombay Stock Exchange (BSE) filing. USFDA released a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed. The stock of Alkem Labs was trading at Rs1,633.60, up 1.56%, from its previous close on BSE.